299 related articles for article (PubMed ID: 30684846)
21. Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer.
Kimura S; Soria F; D'Andrea D; Foerster B; Abufaraj M; Vartolomei MD; Karakiewicz PI; Mathieu R; Moschini M; Rink M; Egawa S; Shariat SF; Gust KM
Clin Genitourin Cancer; 2018 Dec; 16(6):e1123-e1132. PubMed ID: 30061034
[TBL] [Abstract][Full Text] [Related]
22. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
23. Intravesical therapy for bladder cancer.
Patel SG; Cohen A; Weiner AB; Steinberg GD
Expert Opin Pharmacother; 2015 Apr; 16(6):889-901. PubMed ID: 25773220
[TBL] [Abstract][Full Text] [Related]
24. Clinical Role of Programmed Cell Death-1 Expression in Patients with Non-muscle-invasive Bladder Cancer Recurring After Initial Bacillus Calmette-Guérin Therapy.
Fukumoto K; Kikuchi E; Mikami S; Hayakawa N; Matsumoto K; Niwa N; Oya M
Ann Surg Oncol; 2018 Aug; 25(8):2484-2491. PubMed ID: 29717423
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I-II study.
Soria F; Milla P; Fiorito C; Pisano F; Sogni F; Di Marco M; Pagliarulo V; Dosio F; Gontero P
World J Urol; 2016 Feb; 34(2):189-95. PubMed ID: 26026818
[TBL] [Abstract][Full Text] [Related]
26. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
27. HER2 positivity predicts BCG unresponsiveness and adaptive immune cell exhaustion in EORTC risk-stratified cohort of bladder cancer.
Nam W; Chae HK; Jung Y; Kang H; Park M; Choi A; Park JY; Eom DW; Kim SJ
Front Immunol; 2023; 14():1301510. PubMed ID: 38143745
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
29. Upper tract urothelial carcinoma following intravesical bacillus Calmette-Guérin therapy for nonmuscle-invasive bladder cancer: Results from a multi-institutional retrospective study.
Nishiyama N; Hotta H; Takahashi A; Yanase M; Itoh N; Tachiki H; Miyao N; Matsukawa M; Kunishima Y; Taguchi K; Kitamura H; Masumori N
Urol Oncol; 2018 Jun; 36(6):306.e9-306.e15. PubMed ID: 29550096
[TBL] [Abstract][Full Text] [Related]
30. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
[TBL] [Abstract][Full Text] [Related]
31. Prognostic markers of intravesical bacillus Calmette-Guérin therapy for multiple, high-grade, stage T1 bladder cancers.
Lee E; Park I; Lee C
Int J Urol; 1997 Nov; 4(6):552-6. PubMed ID: 9477182
[TBL] [Abstract][Full Text] [Related]
32. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin immunotherapy.
Ajili F; Manai M; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2012 Oct; 36(5):320-4. PubMed ID: 23025650
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
34. Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.
Singla N; Haddad AQ; Passoni NM; Meissner M; Lotan Y
World J Urol; 2017 Jan; 35(1):105-111. PubMed ID: 27194044
[TBL] [Abstract][Full Text] [Related]
35. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
Turker P; Turkeri L
Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
[TBL] [Abstract][Full Text] [Related]
36. Single instillation of mitomycin C plus bacillus Calmette-Guérin (BCG) versus BCG alone in high grade non-muscle invasive bladder cancer.
Weiss BE; Pietzak EJ; Wein AJ; Malkowicz SB; Guzzo TJ
Can J Urol; 2015 Aug; 22(4):7876-81. PubMed ID: 26267025
[TBL] [Abstract][Full Text] [Related]
37. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.
Mmeje CO; Guo CC; Shah JB; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol; 2016 Nov; 70(5):778-785. PubMed ID: 26922408
[TBL] [Abstract][Full Text] [Related]
38. High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study.
Ferro M; Vartolomei MD; Cantiello F; Lucarelli G; Di Stasi SM; Hurle R; Guazzoni G; Busetto GM; De Berardinis E; Damiano R; Perdonà S; Borghesi M; Schiavina R; Almeida GL; Bove P; Lima E; Grimaldi G; Autorino R; Crisan N; Abu Farhan AR; Verze P; Battaglia M; Serretta V; Russo GI; Morgia G; Musi G; de Cobelli O; Mirone V; Shariat SF
Urol Int; 2018; 101(1):7-15. PubMed ID: 29975950
[TBL] [Abstract][Full Text] [Related]
39. Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study.
Liedberg F; Hagberg O; Holmäng S; Hosseini Aliabad A; Jancke G; Ljungberg B; Malmström PU; Åberg H; Jahnson S
Scand J Urol; 2015; 49(4):290-5. PubMed ID: 25624049
[TBL] [Abstract][Full Text] [Related]
40. Clinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder.
Lim SD; Cho YM; Choi GS; Park HK; Paick SH; Kim WY; Kim SN; Yoon G
J Korean Med Sci; 2015 Aug; 30(8):1068-77. PubMed ID: 26240484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
